APA (7th ed.) Citation

McArthur, H. L., Tolaney, S. M., Dent, R., Schmid, P., Asselah, J., Liu, Q., . . . Loibl, S. TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer. SAGE Publishing.

Chicago Style (17th ed.) Citation

McArthur, Heather L., et al. TROPION-Breast04: A Randomized Phase III Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab Versus Standard of Care in Patients with Treatment-naïve Early-stage Triple Negative or HR-low/HER2− Breast Cancer. SAGE Publishing.

MLA (9th ed.) Citation

McArthur, Heather L., et al. TROPION-Breast04: A Randomized Phase III Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab Versus Standard of Care in Patients with Treatment-naïve Early-stage Triple Negative or HR-low/HER2− Breast Cancer. SAGE Publishing.